Clinical Trial Update: Study Evaluating Temsirolimus in Advanced Stage Squamous Cell Carcinoma of the Head & Neck

View source ↗

Summary

The study evaluating temsirolimus in advanced head and neck squamous cell carcinoma has completed; Wyeth is now a subsidiary of Pfizer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Torisel (Temsirolimus)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Squamous Cell Carcinoma | Status: COMPLETED